Atacicept
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
pMN
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Trial Timeline
Jul 7, 2025 → Nov 1, 2027
NCT ID
NCT06983028About Atacicept
Atacicept is a phase 2 stage product being developed by Vera Therapeutics for pMN. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06983028. Target conditions include pMN, IgAN, Nephrotic Syndrome.
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06983028 | Phase 2 | Recruiting |
| NCT07020923 | Phase 2 | Recruiting |
| NCT04716231 | Phase 3 | Active |